First Tracks Biotherapeutics Inc TRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $33.92
- Day Range
- $32.50–35.41
- 52-Week Range
- $14.72–49.91
- Bid/Ask
- $33.00 / $48.00
- Shares Outstanding
- 35.73M
- Market Cap
- $1.19B
- Volume/Avg
- 1M / 783,496
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- —
Valuation
|
Metric
|
TRAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.98 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TRAX
|
|---|---|
Quick Ratio | 13.91 |
Current Ratio | 14.28 |
Interest Coverage | — |
Quick Ratio
TRAX
Profitability
|
Metric
|
TRAX
|
|---|---|
Return on Assets (Normalized) | −30.90% |
Return on Equity (Normalized) | −34.16% |
Return on Invested Capital (Normalized) | −36.94% |
Return on Assets
TRAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R&#z$L | LOCK|$hT& | $128B | |||
| Moderna Inc
MRNA
| LOCK|@wN!$T | LOCK|fK | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#<^x>q | LOCK|w^>@ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|&%M!<m | LOCK|zr< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Z?!j>! | LOCK|M! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|z#w^^^ | LOCK|s<d! | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<@?Dc%c | LOCK|CRt^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$wttt< | LOCK|t? | $24B | |||
| Incyte Corp
INCY
| LOCK|T<!<tc | LOCK|D@! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>cDTdg | LOCK|wF$ | $15B |
United States